Articles related to COMBINATION THERAPY

Treatment options for platinum‑resistant ovarian cancer remain limited. New phase 3 survival data suggest that adding a novel agent to standard chemotherapy may meaningfully extend survival for this hard‑to‑treat population.

As GLP‑1 medications become widely used for obesity and metabolic disease, clinicians are confronting a growing question: What should be done when patients don’t respond as expected?

The combined action of the drugs results in pupil constriction, resulting in a pinhole effect that improves near visual acuity and depth of focus in patients with presbyopia.

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

Castalin can boost the effectiveness of CHK1 inhibitors, a class of drugs currently in phase 1 clinical trials. When tested in cellular models of triple-negative breast cancer, one of the most aggressive forms of the disease, Castalin was shown to enhance the action of these inhibitors.

“Progress is sort of stepwise. How do we make things better? And what we see with FLAURA2 is that we do see an improvement in survival – a meaningful improvement in survival.” – Dr. Stephen Liu